Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group Confirmatory Phase 3 results expected early in second quarter Potential application in people who need immediate protection or respond poorly to vaccination REGEN-COV 1,200 mg administered by subcutaneous injection, providing greater convenience and efficiency than infusion Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial results from a...